Neurocrine Biosciences and [AMPH, COLL, IRWD, ANIP, DCPH, ALKS, AVDL, ITCI, DVAX, PCRX, EGRX, PBH, EVO, SUPN] Capital-Expenditures Over Time

Neurocrine Biosciences Capital Expenditures Over Time

NBIX Stock  USD 134.96  0.49  0.36%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Neurocrine Biosciences Performance and Neurocrine Biosciences Correlation.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.
  
Capital Expenditures is likely to rise to about 29.7 M in 2024.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurocrine Biosciences. If investors know Neurocrine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurocrine Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.512
Earnings Share
3.76
Revenue Per Share
22.422
Quarterly Revenue Growth
0.247
Return On Assets
0.118
The market value of Neurocrine Biosciences is measured differently than its book value, which is the value of Neurocrine that is recorded on the company's balance sheet. Investors also form their own opinion of Neurocrine Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Neurocrine Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurocrine Biosciences' market value can be influenced by many factors that don't directly affect Neurocrine Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurocrine Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurocrine Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurocrine Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Capital Expenditures Analysis

Compare Neurocrine Biosciences and related stocks such as Amphastar P, Collegium Pharmaceutical, and Ironwood Pharmaceuticals Capital Expenditures Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
201020112012201320142015201620172018201920202021202220232024
AMPH10.7 M10.7 M25.2 M18.3 M20.5 M16 M21.4 M35.1 M46.8 M41.6 M33.9 M27.5 M24 M38.2 M30.4 M
COLL206 K206 K206 K206 KK362 KM990 K24.4 M6.4 M373.8 M1.9 M1.6 M461 K437.9 K
IRWD2.7 M9.7 M14 M9.6 M3.5 MM104.2 M4.2 M8.6 M7.2 M1.8 M265 K136 K273 K259.4 K
ANIP125 K719.9 K611.2 K191 K35.8 M32.7 M149.1 M108 M10.9 M27.5 M68.3 M23.6 M16.5 M18.5 M20.9 M
ALKS800 K17 M22.2 M19.1 M33.7 M52.9 M43.7 M51.3 M69.4 M90.9 M42.2 M29 M38.3 M48 M28.3 M
AVDL1.5 M1.9 M1.1 MM1.7 M1.6 M1.2 M53.7 M20.2 M29 K98 K26 K716 K0.00.0
ITCI18 K18 K39 K33.3 K11.8 K860.6 K49 K723.4 K391.3 K700.4 K266.7 K325.7 K778 K269 K377.9 K
PCRX5.8 M6.2 M18.3 M12.8 M21.9 M41.3 M24.7 M19.3 M14.5 M10.2 M37.8 M45.9 M30.1 M15.2 M21.7 M
PBH0.0606 K10.3 M2.8 M6.1 M3.6 MM12.5 M10.5 M17.3 M22.2 M9.6 M7.8 M9.6 M6.6 M
EVO0.08.1 M10.2 M5.2 M5.3 M11.5 M10.1 M17.6 M27.9 M31.9 M99.1 M118.9 M181.4 M216 M226.8 M
SUPN1.1 M685 K753 K2.4 M593 K2.1 M1.6 MM844 K2.7 M3.4 MM412 K551 K523.5 K
JavaScript chart by amCharts 3.21.15Macroaxis Charts2012201420162018202020222024 50M100M150M200M250M300M350M
JavaScript chart by amCharts 3.21.15Amphastar Ptotal: 400.3MCollegium Pharmaceuticaltotal: 414.2MIronwood Pharmaceuticalstotal: 170.5MANI Pharmaceuticalstotal: 513.4MAlkermes Plctotal: 586.8MIntracellular Thtotal: 4.9MPacira BioSciences,total: 325.5MSupernus Pharmaceuticalstotal: 21.7M

Neurocrine Biosciences and related stocks such as Amphastar P, Collegium Pharmaceutical, and Ironwood Pharmaceuticals Capital Expenditures description

Capital Expenditures are funds used by Neurocrine Biosciences to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Neurocrine Biosciences operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

My Equities

My Current Equities and Potential Positions

Neurocrine Biosciences
NBIX
ClassificationObamacare Repeal
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 128.51
100%

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.